<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611905</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00179210</org_study_id>
    <secondary_id>R01HL131829</secondary_id>
    <nct_id>NCT05611905</nct_id>
  </id_info>
  <brief_title>Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid</brief_title>
  <official_title>Phase 1 Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid (11C-PABA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will perform radionuclide PET scans in subjects with infectious diseases to&#xD;
      assess whether radio-labeled PABA (11C-PABA) is effective for infection imaging.&#xD;
&#xD;
      Tomographic imaging can be used to evaluate disease processes deep within the body,&#xD;
      noninvasively and relatively rapidly. The goal is to see if this imaging technique can help&#xD;
      differentiate infections from non-infectious processes and also provide information on the&#xD;
      causative bacterial class.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2023</start_date>
  <completion_date type="Anticipated">November 26, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pathophysiology of 11C-PABA in diseased subjects</measure>
    <time_frame>Up to 3 hours</time_frame>
    <description>Reconstruction of the PET data will be performed by means of iterative reconstruction (IR) by the ordered subset-expectation-maximization (OSEM) method with CT attenuation correction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biodistribution of 11C-PABA in diseased subjects</measure>
    <time_frame>Up to 3 hours</time_frame>
    <description>Reconstruction of the PET data will be performed by means of iterative reconstruction (IR) by the ordered subset-expectation-maximization (OSEM) method with CT attenuation correction.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Excretion</condition>
  <condition>Bacterial Infections</condition>
  <condition>Inflammatory Disease</condition>
  <condition>Oncologic Disease</condition>
  <arm_group>
    <arm_group_label>11C-para-aminobenzoic acid PET/CT</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>11C-para-aminobenzoic acid PET/CT</intervention_name>
    <description>A bolus of 20 mCi of 11C-PABA followed by PET/CT</description>
    <arm_group_label>11C-para-aminobenzoic acid PET/CT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probenecid</intervention_name>
    <description>Oral dose of 500 mg (tablet) 2 hours before IV dose of 11C-PABA will be administered.</description>
    <arm_group_label>11C-para-aminobenzoic acid PET/CT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with bacterial infections or non-infectious processes such as inflammatory /&#xD;
        oncologic diseases will be enrolled. Males and female members of all races and ethnic&#xD;
        groups are eligible for this trial and encouraged to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female â‰¥18 years of age at the time of consent and imaging&#xD;
&#xD;
          2. Those with confirmed diagnosis of infection at any body site OR clinical and imaging&#xD;
             evidence of suspected infection in any body site OR confirmed inflammatory oncologic&#xD;
             disease.&#xD;
&#xD;
          3. Assessed to be in stable condition to participate in the study&#xD;
&#xD;
          4. Subject is judged by the investigator to have the initiative and means to be compliant&#xD;
             with the protocol.&#xD;
&#xD;
          5. Subjects or their legal representatives must have the ability to read, understand and&#xD;
             provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Lactating females&#xD;
&#xD;
          3. History of significant renal or hepatobiliary diseases&#xD;
&#xD;
          4. Inadequate venous access&#xD;
&#xD;
          5. Administered a radioisotope within 5 physical half-lives prior to study enrollment&#xD;
&#xD;
          6. Treated with an investigational drug / biologic / therapeutic device within 30 days&#xD;
             prior to study&#xD;
&#xD;
          7. Determined to have prior (external) radiation exposure of 5 rems in past year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sanjay K Jain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sanjay K Jain, MD</last_name>
    <phone>4105028241</phone>
    <email>sjain5@jhmi.ed</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institutions</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay K Jain, MD</last_name>
      <phone>410-502-8241</phone>
      <email>sjain5@jhmi.ed</email>
    </contact>
    <investigator>
      <last_name>Sanjay K Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>March 10, 2023</last_update_submitted>
  <last_update_submitted_qc>March 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>Probenecid</keyword>
  <keyword>11C-PABA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Probenecid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

